Igarashi A, Nakagawa H, Morita A, et al. - A multinational, randomized, double‐blind, placebo‐controlled study was conducted to assess outcomes in Japanese patients with plaque psoriasis who were treated with tildrakizumab. Researchers randomized adults with moderate to severe plaque psoriasis in a 2:2:1 ratio to receive subcutaneous tildrakizumab 100 mg or 200 mg or placebo every 12 weeks. They re-randomized placebo recipients to tildrakizumab 100 or 200 mg at week 12. There were 158 Japanese patients randomized to tildrakizumab 100 (n = 64) or 200 mg (n = 62) or placebo (n = 32) included in the analysis. The data showed that tildrakizumab was overall well tolerated with an adverse event profile comparable to that of placebo. Despite greater baseline disease severity vs the global reSURFACE 1 population, tildrakizumab treatment was correlated with durable effectiveness in Japanese patients with moderate to severe plaque psoriasis. Significantly more Japanese patients receiving tildrakizumab 100 and 200 mg vs placebo achieved PASI 75 (54.7% and 54.8% vs 6.3%, respectively) and PGA 0/1 response (54.7% and 56.5% vs 9.4%, respectively) at week 12. Response rates increased over time with maximum effectiveness after 22‐28 weeks.